Fusobacterium nucleatum cDNA and Antigen

Fusobacterium nucleatum is a type of bacteria that can cause infections in humans, particularly in the mouth and gastrointestinal tract. Researchers have identified several protective antigens produced by this bacterium, including the 34 kDa membrane antigen, Surface antigen, sub nucleatum Cell surface protein, and 60 kDa chaperonin. In this article, we will explore the potential of these protective antigens in preventing infections and improving health.

Protective antigens are substances that can trigger an immune response in the body, leading to the production of antibodies that can protect against harmful bacteria. Studies have shown that these protective antigens produced by Fusobacterium nucleatum can provide immunity against the bacterium in animal models. Therefore, individuals who are exposed to the bacterium can potentially be protected from developing infections.

One of the protective antigens produced by Fusobacterium nucleatum is the 34 kDa membrane antigen. This protein is present on the surface of the bacterium and plays a crucial role in its virulence. However, it has also been found to elicit a strong immune response in animal models, making it a promising candidate for vaccine development.

Surface antigen and sub nucleatum Cell surface protein are two other important protective antigens produced by Fusobacterium nucleatum. Surface antigen is a protein that helps the bacterium to attach to host cells, but it can also stimulate the production of antibodies that can protect against infection. Sub nucleatum Cell surface protein is a structural component of the bacterium’s outer membrane that has been shown to provide immunity in animal models.

The 60 kDa chaperonin is another protective antigen produced by Fusobacterium nucleatum. This protein plays a role in the bacterium’s ability to survive under stressful conditions, but it has also been found to elicit an immune response in animal models.

In conclusion, the discovery of protective antigens such as the 34 kDa membrane antigen, Surface antigen, sub nucleatum Cell surface protein, and 60 kDa chaperonin has provided new hope in the fight against Fusobacterium nucleatum infections. By understanding the potential of these protective antigens, scientists can develop effective vaccines that can improve health and prevent the spread of the bacterium.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Fusobacterium nucleatum cDNA and recombinant antigens can be used in various biomedical applications. For instance, cDNA can be used to clone, sequence and characterize new F. nucleatum genes. Recombinant antigens can be used in diagnostic tests to detect F. nucleatum infection, as well as in vaccine development to protect against infection. Additionally, cDNA and recombinant antigens can be used to study the interaction between F. nucleatum and other organisms, such as the human microbiome.